Antiretroviral therapy in intensive care;Le traitement antirétroviral en réanimation

Medecine et Maladies Infectieuses

Volumn 41, Issue 7, 2011, Pages 353-358

  Lanoix, J P ^a   Andrejak, C ^a   Schmit, J L ^a  

^a AMIENS UNIVERSITY HOSPITAL   (France)

Author keywords

Antiretroviral; HIV; ICU

Indexed keywords

ABACAVIR; ANTICONVULSIVE AGENT; ANTIRETROVIRUS AGENT; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ETRAVIRINE; FENTANYL; FOSAMPRENAVIR; INDINAVIR; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MIDAZOLAM; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROPOFOL; PROTEINASE INHIBITOR; PROTON PUMP INHIBITOR; RALTEGRAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; UNINDEXED DRUG; ZIDOVUDINE;

ANTIVIRAL THERAPY; CD4 LYMPHOCYTE COUNT; CREATININE CLEARANCE; DRUG ANTAGONISM; DRUG CONTRAINDICATION; DRUG FORMULATION; DRUG INDICATION; DRUG POTENTIATION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; GLOMERULUS FILTRATION RATE; HOSPITAL ADMISSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INTENSIVE CARE UNIT; KIDNEY FAILURE; LIVER FAILURE; MULTIPLE CYCLE TREATMENT; REVIEW; RISK ASSESSMENT; STOMACH TUBE; SURVIVAL RATE; TUBERCULOSIS; VIRUS LOAD; VIRUS RESISTANCE;

ACUTE KIDNEY INJURY; ANTI-HIV AGENTS; CRITICAL ILLNESS; DECISION TREES; DOSAGE FORMS; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG UTILIZATION; HIV INFECTIONS; HUMANS; INTENSIVE CARE; LIVER FAILURE; RENAL REPLACEMENT THERAPY; VIRAL LOAD;

EID: 79960903307     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/j.medmal.2011.05.001     Document Type: Review

References (26)

1. Institut de veille sanitaire. Surveillance du Sida 2008 [en ligne], [Page consultée le 08/09/2010]. http://www.invs.sante.fr/cgibin/broker.exe%3Fok=ok%26_service=InVS%26_program=sid_prog.fichier_sida_total.sas.
2. Casalino E., Wolff M., Ravaud P., Choquet C., Bruneel F., Regnier B. Impact of HAART advent on admission patterns and survival in HIV-infected patients admitted to an intensive care unit. AIDS 2004, 18(10):1429-1433.
3. Vincent B., Timsit J.F., Auburtin M., Schortgen F., Bouadma L., Wolff M., et al. Characteristics and outcomes of HIV-infected patients in the ICU: impact of the highly active antiretroviral treatment era. Intensive Care Med 2004, 30(5):859-866.
4. Powell K., Davis J.L., Morris A.M., Chi A., Bensley M.R., Huang L. Survival for patients with HIV admitted to the ICU continues to improve in the current era of combination antiretroviral therapy. Chest 2009, 135(1):11-17.
5. Palacios R., Hidalgo A., Reina C., de la Torre M., Marquez M., Santos J. Effect of antiretroviral therapy on admissions of HIV-infected patients to an intensive care unit. HIV Med 2006, 7(3):193-196.
6. Dickson S.J., Batson S., Copas A.J., Edwards S.G., Singer M., Miller R.F. Survival of HIV-infected patients in the intensive care unit in the era of highly active antiretroviral therapy. Thorax 2007, 62(11):964-968.
7. Zolopa A., Andersen J., Powderly W., Sanchez A., Sanne I., Suckow C., et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One 2009, 4(5):e5575.
8. Bourgarit A., Carcelain G., Martinez V., Lascoux C., Delcey V., Gicquel B., et al. Explosion of tuberculin-specific Th1-responses induces immune restoration syndrome in tuberculosis and HIV co-infected patients. AIDS 2006, 20(2):F1-F7.
9. French M.A. HIV/AIDS: immune reconstitution inflammatory syndrome: a reappraisal. Clin Infect Dis 2009, 48(1):101-107.
10. Manabe Y.C., Campbell J.D., Sydnor E., Moore R.D. Immune reconstitution inflammatory syndrome: risk factors and treatment implications. J Acquir Immune Defic Syndr 2007, 46(4):456-462.
11. Jevtovic D.J., Salemovic D., Ranin J., Pesic I., Zerjav S., Djurkovic-Djakovic O. The prevalence and risk of immune restoration disease in HIV-infected patients treated with highly active antiretroviral therapy. HIV Med 2005, 6(2):140-143.
12. Shelburne S.A., Visnegarwala F., Darcourt J., Graviss E.A., Giordano T.P., White A.C., et al. Incidence risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS 2005, 19(4):399-406.
13. Blanc F.X. Cambodian early vs late introduction of ARVs. Internationnal AIDS conference 2010, [Abstract].
14. Berns J.S., Kasbekar N. Highly active antiretroviral therapy and the kidney: an update on antiretroviral medications for nephrologists. Clin J Am Soc Nephrol 2006, 1(1):117-129.
15. Yeni P. Prise en charge médicale des personnes infectées par le VIH. Rapport 2010 2010, La documentation française, Paris, p. 417.
16. Bartlett J.G., Gallant J.E. 2005-2006 medical management of HIV infection 2005, Johns Hopkins medicine health publishing business group, Baltimore, p. 482.
17. Pialoux G., Housset C. Manifestation hépatiques et biliaires. VIH 2007, 147-157. Doin Éditeurs, Reuil-Malmaison. Édition 2007. P.M. Girard, C. Katlama, G. Pialoux (Eds.).
18. Abdool Karim S.S., Naidoo K., Grobler A., Padayatchi N., Baxter C., Gray A., et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010, 362(8):697-706.
19. Croda J., Croda M.G., Neves A., De Sousa dos Santos S. Benefit of antiretroviral therapy on survival of human immunodeficiency virus-infected patients admitted to an intensive care unit. Crit Care Med 2009, 37(5):1605-1611.
20. Khouli H., Afrasiabi A., Shibli M., Hajal R., Barrett C.R., Homel P. Outcome of critically ill human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy. J Intensive Care Med 2005, 20(6):327-333.
21. Dinh A., Salomon J., Vuagnat A., De Truchis P., Maury E., Bernard L. Antiretroviral therapy in critically ill patients: a French national study. Med Mal Infect 2007, 37(12):809-815.
22. El-Sadr W.M., Lundgren J.D., Neaton J.D., Gordin F., Abrams D., Arduino R.C., et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006, 355(22):2283-2296.
23. Ribaudo H.J., Haas D.W., Tierney C., Kim R.B., Wilkinson G.R., Gulick R.M., et al. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an adult AIDS clinical trials group study. Clin Infect Dis 2006, 42(3):401-407.
24. Joly V., Yeni P. Non-nucleoside reverse transcriptase inhibitors. Ann Med Interne (Paris) 2000, 151(4):260-267.
25. Arnedo-Valero M., Garcia F., Gil C., Guila T., Fumero E., Castro P., et al. Risk of selecting de novo drug-resistance mutations during structured treatment interruptions in patients with chronic HIV infection. Clin Infect Dis 2005, 41(6):883-890.
26. Yerly S., Fagard C., Gunthard H.F., Hirschel B., Perrin L. Drug resistance mutations during structured treatment interruptions. Antivir Ther 2003, 8(5):411-415.